A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 22.6% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: transplantcellstemplacebohematopoietic
  Phrases that lowered it: participantseffect ofclinical trialuse ofallergy
• Phase: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 51 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 14.0% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 83.0% (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 257 (lowers risk) · Sponsor's track record
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit NCT00549393 · started 2008 · scored riskier than 42% of active trials completed
• Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age NCT02326467 · started 2016 · scored riskier than 71% of active trials completed
• 2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients NCT02490631 · started 2015 · scored riskier than 29% of active trials completed
• Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor NCT03423147 · started 2018 · scored riskier than 14% of active trials terminated
• Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects NCT02222896 · started 2014 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.